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ABSTRACT 
 
 
The Influenza-A virus is a highly pathogenic virus with the potential to cause 
major pandemics and annual outbreaks.  The goal of this project was to investigate the 
highly conserved trimeric polymerase complex of the virus, which is needed for viral 
replication and transcription. We developed the reagents for a fluorescence polarization 
assay to help identify small molecules that disrupt the interactions within the complex, 
and have the potential to be a new anti-viral drug.  This project also developed a 
transcription assay system to test the polymerase fidelity. 
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BACKGROUND 
 
 
Influenza  
 
 Influenza, also known as the flu or la grippe, is a serious respiratory illness which 
is caused by infection with influenza virus. The disease is very contagious, can cause 
symptoms ranging from mild to very severe, and can even cause death, especially in 
young children, and the elderly.  
 There have been several devastating influenza outbreaks throughout human 
history. One of the worst was the Spanish flu outbreak of 1918. At this time, Type A 
H1N1 influenza infected almost one third of the total world population, killing about 50 
million people. This Spanish flu was assumed to be the ancestor to all other Type A 
infections since; however we have never seen as extreme of a pathogenicity since 
(Taubenberger and Morens, 2006). Since 1918, there have been a number of other serious 
outbreaks of the flu, including Russian flu in the late 1800s, Asian flu in the 1950s, and 
Hong Kong flu in the 1960s. In the more recent past, there have been outbreaks of Avian 
flu and the Swine flu in 2009-2010, which has killed over 18,000 people worldwide 
(H1N1, 2010). 
 In addition to these serious pandemics, influenza is also an annual seasonal 
disease, occurring during autumn and winter in temperate regions. Worldwide, influenza 
results in three to five million cases of severe illness a year. The number of deaths from 
annual influenza varies, but the Center for Disease Control and Prevention estimates 
between 3,000 and 49,000 people worldwide will die from flu-related causes each year. 
While anyone can be infected with influenza, the most susceptible to infection are the 
very young, the elderly, and people with other medical conditions. These groups are also 
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the most likely to die from influenza – almost 90% of flu deaths occur in these 
populations (Influenza [Seasonal], 2009). 
 In humans, influenza infection targets the respiratory tract. The flu can cause 
many different symptoms, such as fever, chills, cough, sore throat, head and body aches, 
runny or stuffy nose, fatigue, and vomiting/diarrhea. Affected persons may experience 
some or all of these symptoms. A typical flu infection lasts anywhere from two days to 
two weeks, but some people may develop further complications such as pneumonia or 
bronchitis, especially those who are already at risk (Influenza [Seasonal], 2009). 
 
Influenza Virus  
Nomenclature 
 The influenza virus is divided into three types – A, B and C – based upon the type 
of nucleocapsid found within the virus. Type A is responsible for the majority of annual 
flu outbreaks and pandemics. Type B causes sporadic outbreaks, while Type C typically 
only causes mild illness. Only Type A is then divided into further subtypes based on the 
different combinations of viral surface proteins that it contains. Types A and B can also 
be further classified into strains, or grouped by low/high pathogenicity (“Influenza 
Viruses”, 2005). 
 There are 16 hemagglutinin (HA) subtypes, and only three are found in humans. 
Additionally, there are 9 neuraminidase (NA) subtypes, two of which are found in 
humans (Kimball, 2010). The combination of the two HA and NA proteins is where the 
influenza strains such as H1N1 or H3N2 get their names from. The different 
combinations of these glycoproteins allow for infection in specific species, such as 
 7 
humans or avian species. This species specificity occurs because of the structures of the 
HA and NA proteins. These proteins bind to species-specific proteins on the host cell 
surface (Squires and Scheuermann, 2006).  
 
Structure 
 Influenza A viruses are lipid-enveloped viruses which come in different shapes 
and sizes – from spherical virions about 100nm in diameter to long filamentous particles. 
The influenza virus contains a genome of eight strands of negative-sense RNA. This 
genome, made up of segments ranging from 890 to 2341 nucleotides, encodes ten viral 
proteins which make up the influenza A virion. Due to this segmented genome, 
reassortment, recombination of the virus genes, is common. In mixed infections with 
more than one strain of influenza, combinations of gene segments can be exchanged 
(Steinhauer and Skehel, 2002). This can lead to antigenic shift. Antigenic shift is very 
dangerous because if it leads to new combinations of surface proteins, then the immune 
system or vaccines will not target the virus (Staley et al., 2007). 
 Each of the eight gene segments encodes one or more viral proteins. The three 
largest segments encode the polymerase proteins, PA, PB1 and PB2. The polymerase 
proteins are named for their acidic or basic properties, respectively. The polymerase 
proteins have a number of functions, including transcribing mRNAs, synthesizing 
cRNAs, and transcribing cRNAs into viral gene segments for progeny. The fourth gene 
segment encodes hemagglutinin, or HA, which is involved in membrane fusion with host 
cells and neutralizing host antibodies. The fifth segment encodes the nucleoprotein, or 
NP. This protein encapsulates the genetic material of the virus (cRNAs and vRNAs), and 
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is associated with the three polymerase subunits. Gene segment six encodes 
neuraminidase, or NA, which is involved with cleavage at the end of the viral life cycle to 
allow the virions to be released. The seventh segment encodes two different proteins due 
to RNA splicing. The first is matrix protein M1, which is involved with virus assembly 
and budding. This is the most abundant protein. The second is transmembrane protein 
M2, which is involved with virus disassembly. Finally, the eighth gene segment encodes 
NS1 and NS2.  NS1 is a regulator of splicing and translation, while NS2 mediates 
transport in and out of the nucleus. These two proteins were originally thought to be non-
structural proteins (hence the name), but there has since been evidence proving otherwise 
(Steinhauer and Skehel, 2002). 
 
Infection and Replication 
In an influenza infection, the virus first invades cells of respiratory passage. The 
surface HA molecules bind to sialic acid residues on proteins of the epithelial cells of the 
respiratory system, and the virus is then engulfed by the host cell. While in the endocytic 
vessel, there is a drop in pH which causes a change to the HA protein. This change 
enables the fusion of the viral membrane with the vesicle membrane, allowing the viral 
contents to be exposed to the cell. The viral RNA is then replicated by the viral 
polymerase protein (made up of PA, PB1, and PB2, in conjunction with NP). The host 
cell’s machinery is then used for translation to create new viral proteins (Kimball, 2010). 
The virus particle formation occurs at the cell membrane. Budding occurs from the 
sections of the membrane where viral glycoproteins hemagglutinin and neuraminidase 
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have accumulated (Steinhauer and Skehel, 2002). The infection then continues to new 
cells. 
 
Drugs and Vaccines 
 Antibodies produced by humans against virus activity are directed against the 
viral surface proteins. However, the influenza viruses are continually evolving to evade 
existing human immunity. This allows infection to continue happening. To combat this, 
medical professionals have developed a number of antiviral drugs (to be taken once 
infection has already occurred), as well as vaccines. 
There are two methods of vaccination against influenza: a trivalent, inactivated 
vaccine (the “flu shot”), and a live vaccine which comes in the form of a nasal spray 
(FluMist). The major difference in the vaccinations is the method of delivery. The nasal 
spray is made of very low titer live virus, which has a non-existent virulence. Both 
vaccines are made of three current viruses – two A strains and a B strain. The two types 
of vaccine provide different immune responses. The flu shot elicits good serum antibody 
response, but poor induction of IgA antibodies and cell mediated immunity. The live 
nasal spray, on the other hand, produces a more long lasting immune response similar to 
natural immunity (Cox et al., 2004). However, the flu shot seems to be more effective 
despite the nasal spray having a better immune response (Monto et al., 2009). 
 For those who did not get the vaccine, there are also two main types of antiviral 
drugs. The first antiviral drug was amantadine. Amantadine, along with the related 
compound rimantadine, was first discovered to have anti-influenza properties in the 
1960s. This drug works by two mechanisms. The first mechanism, which takes place at 
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concentrations of 100µM or greater, is a broad antiviral activity. This occurs due to the 
compound’s weak basic properties. The second, at concentrations of 5µM or less, is a 
specific activity against several strains of influenza A (no effect on influenza B or C). At 
this concentration, the compound affects the gene segment responsible for M1 and M2, 
and causes a change in the pH composition in the cells (Steinhauer and Skehel, 2002). 
Virtually all strains of influenza A have developed resistance to this drug (Kimball, 
2010). 
 The second main set of antiviral drugs are oseltamivir and zanamivir. These drugs 
act against the NA protein, preventing it from binding to sialic acid (Steinhauer and 
Skehel, 2002). This prevents the release and spread of fresh virions. All H1N1 strains 
circulating in the US by the 2008-2009 flu season were resistant to Tamiflu (brand name 
oseltamivir) (Kimball, 2010). There has been widespread resistance to these drugs as 
early as 2007 and it has only gotten worse since then (McKimm-Breschkin, et al., 2007). 
 Antiviral drugs are difficult to find due to the mechanisms of viruses. Viruses rely 
heavily on the host cell they are in to supplement its life cycle. There are many agents 
which could kill off the virus, but they would also kill part of or the entire host cell, thus 
detrimental to the human (Kimball, 2010). Additionally, it is easiest to make drugs 
targeting the surface proteins of the virus – but these are the first to be changed and adapt, 
thus rendering the drugs useless. The goal for new antiviral drugs is to target molecular 
machinery specific to the virus (Liu, et al., 2007) – something we aim to do with this 
project. 
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Influenza Polymerase 
 The polymerase complex is comprised of three proteins (PA, PB1 and PB2). All 
three proteins are required for both viral replication and transcription. PB1 is located at 
the core of the complex, and the complex is formed by separate interactions between PB1 
and PA, and PB1 and PB2. Several of the key protein-protein interactions involved in the 
formation of the 3P complex have been previously described. They include the binding of 
the C-terminus of PA to the N-terminal domain of PB1, the binding of the C-terminus of 
PB1 to the N-terminal domain in PA, and the binding of the C terminus of PB2 to a 
poorly defined structure of PB1 (Bradel-Tretheway, et al., 2008). These interactions are 
critical to the formation of the polymerase complex, and thus the viability of the virus as 
a whole. 
 
Polymerase Interaction Targeting 
 There is a need for new antiviral drugs that have a low potential of being 
susceptible to viral resistance. Targeting the interactions within the polymerase complex 
for drug design is appealing, because the proteins contain highly conserved peptide 
sequences which are found among most influenza A viruses, including highly pathogenic 
strains with pandemic potential (Heiny et al., 2007). Among the binding region of PA 
(composed of 406 residues), there are only 13 which are not conserved between different 
H1N1 and avian strains. Similarly, the region of PB1 which binds to PA (70 residues), 
there are only 2 which are not conserved (Obayashi et al., 2008). 
 To target the interaction between the PA and PB1 proteins, we will be using a 
Fluorescence Polarization Assay. The theory of the fluorescence polarization assay is that 
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larger molecules rotate slower than smaller ones, and thus emit more light in a more 
concentrated direction (more polarized) when polarized light is passed through them 
(Figure-1). Smaller molecules rotate faster, and therefore emit light in different 
directions (depolarized) when shot with polarized light. In this system, the PB1 peptide 
alone would rotate more quickly, whereas once it is bound to PA it would rotate more 
slowly. To perform the assay, PB1 samples are added to a 384-well plate and mixed with 
PA. The change in fluorescence polarization of the labeled peptide is measured. The 
chemical library can then be screened for chemical compounds that inhibit the PA-
dependent fluorescence polarization. If PA/PB1 binding is interrupted the fluorescence 
will be depolarized after the chemical compound is added.  
 
 
Figure 1: Illustration of the Fluorescence Polarization Assay. This figure shows the concept of the FP 
assay. A small molecule (PB1 with a chromophore attached) would rotate rapidly, leading to depolarized 
light. A larger molecule (PB1 bound to PA) would rotate more slowly, giving polarized light. 
 
Polymerase Fidelity 
 The high genetic diversity of the influenza A virus, together with the previously 
discussed gene reassortment, allows the influenza virus to acquire its efficient host 
adaptability. One suggested mechanism for this efficient evolutionary process was a 
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highly error-prone replication process. Every genome copy packaged in a new virus has 
been synthesized by the influenza polymerase, and thus it has been assumed that the 
error-prone polymerase was responsible for generating mutations which allowed the virus 
to evolve. In a similar virus with high mutation rates, the HIV-1 DNA polymerase is well 
known as an error prone polymerase (Ji and Loeb, 1992). However, in a recent 
publication, the influenza polymerase was found to have a high fidelity, with a much 
lower rate of mis-incorporation than the HIV-1 DNA polymerase (Aggarwal et al., 2010). 
In this report, the PA, PB1 and PB2 genes from the H3N2 strain were cloned into a 
baculovirus expression vector, and transfected into Sf9 insect cells to produce the 
recombinant viral proteins. The three recombinant viruses were then used to coinfect Tni 
insect cells, and the lysates were purified using the TAP purification technique as 
described previously (Bradel-Tretheway et al., 2008; Puig et al., 2001). The purified 
polymerase complex was then used in an newly developed ApG initiated transcription 
assay (see Methods section). This study found that high influenza activity in this assay 
system. In further mis-incorporation studies, influenza polymerase was found to have a 
high fidelity, and it was concluded that this must be because the influenza polymerase 
does all the viral replication itself rather than using host mechanisms. Having a low 
fidelity (error prone) polymerase would cause catastrophic mutations and inhibit the virus 
from further infection. In contrast, HIV-1 RT only replicates the viral DNA once and then 
the host proteins take over. In comparison to past transcription assay systems, this study 
eliminated the biased NTP pool which was often seen before (Aggarwal et al., 2010). 
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PROJECT PURPOSE 
 
 
 A need for new antiviral drugs has been demonstrated due to the high viral 
resistance to current drugs.  This project will develop a protocol for preparing reagents 
(influenza polymerase constructs) to be used in an assay system which will screen 
libraries of compounds which disrupt the interaction between PA-GST fusion proteins 
and PB1 peptides. These compounds then can be further tested for their ability to directly 
inhibit the influenza A virus. 
 Additionally, the influenza polymerase has always been assumed be a low fidelity 
enzyme, until recently. The influenza polymerase (strain H3N2) was found to have high 
fidelity when the proteins are grown in insect cells. The project will also develop new 
assay conditions to attempt to further characterize the polymerase’s fidelity with 
mammalian host proteins, as well as with different strains of influenza.  
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METHODS 
 
Cloning and Expression of PA-H5N1 protein constructs 
 
Two separate constructs were created: H5N1-PA239-716 and H5N1-PA657-716.  The 
larger protein has been recognized as the main binding segment of PA to PB1, while the 
smaller one includes the sites required for binding (Obayashi et al., 2008). DNA 
fragments encoding portions of the Influenza A PA protein were amplified by polymerase 
chain reaction (PCR) using full length PA as a template and a set of primers: (5′-
CCATTCCATGGGAATGTGCAAAACCCCGAG-3′ and 5′-
CATGAGAATTCTCAAGGGCAGGGTTTGTA-3′ (PA239-716) or 5’-
TACAGATAAGGATTCCCGACAGTTGTAA-3’ (PA657-716)).  The PCR conditions 
were 94 °C for 3 min followed by 30 cycles (94 °C for 1 min, 60°C for 1 min and 72°C 
for 1 min) and finally 72 °C for a 5-min extension.  Primers were synthesized through the 
University of Rochester Functional Genomics center. The DNA was amplified using a 
routine Deep Vent PCR Reaction (New England Biolabs), using Deep Vent DNA 
polymerase. The PCR products were then gel purified and the amplified fragments were 
then digested with BamHI and XhoI restriction enzymes and ligated into pGEX-5x-1 
vector (Novagen) in frame with the N-terminally located glutathione S-transferase (GST).  
The plasmid was ligated using T4 DNA Ligase in a 6:1 insert:vector ratio for 2hr at room 
temperature. The sequence of the pGEX-PA plasmids were verified by DNA sequence 
analysis, and the ligation was verified through gel electrophoresis.  
The plasmids were then transformed into E. coli BL21-Codon Plus competent 
cells using electrotransformation. 1µL DNA was added to 25µL competent cells. The 
electroporation apparatus was set to 1.8kV, 25µF, with a pulse of 200 ohms. The cells 
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were grown with 500mL of S.O.C.  and the resulting suspension was placed in a floor 
shaker at 225rpm at 37°C for one hour to allow expression of the ampicillin gene. 20µL 
and 200µL samples were then spread on an LB+ampicillin plate overnight at 37°C. 
The next day, colonies were picked and placed in 10 ml LB Broth and grown for 
2 hours at 37°C in the floor shaker. After incubation, the suspension was used to 
inoculate 1L of LB broth, and grew for another 3 hours. The cultures were then induced 
overnight with 0.5mM IPTG at room temperature. The following day, the GST-
purification of the proteins could be completed (see Results). 
The PB1 binding region of the peptide (residues 1-25) was purchased already 
labeled with a Rhodamine chromophore (Invitrogen) for use in the Fluorescence 
Polarization Assay. Mutations to the PA construct were introduced with site-directed 
mutagenesis (Quick-Change mutagenesis kit, Stratagene). 
 
Cell Culture 
 Human lung endothelial cells (A549) were grown at 37°C and maintained in 
DMEM solution supplemented with 10% fetal bovine serum, 2mM glutamine, 50 IU 
penicillin ml
-1
, and 50µg streptomycin ml
-1
. 
 
Adenovirus production 
 Previously, recombinant adenoviruses expressing PA, PB1 and PB2 were created 
from pShCMV by homologous recombination into AdEasy and propogation in 
HEK293A cells (AdEasy system, Stratagene) (Luo, et al., 2007). Viral titres were 
determined by quantitative real-time PCR. Viruses were purified by CsCl density 
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gradient centrifugation as well as dialysis. PA was tagged with a tandem-affinity 
purification tag (TAP tag) (Bradel-Tretheway, et al., 2008). 
 
Polymerase purification 
 A549 cells (7-8 x 10
6
 cells in a T225 flask) were transduced with each of the three 
adenoviruses (rAd5-PA-TAP, PB1, PB2) at an m.o.i. of 1000, except the H5N1 strain for 
which a m.o.i. of 100 was used. Recombinant adenoviruses from the following strains 
were used: H5N1 (VN1203), 1918, H1N1 (A/California/04/09), and WSN (A/WSN/33). 
Lysates were prepared 48 hours post infection and were purified using the TAP method 
as described previously (Bradel-Tretheway, et al., 2008; Puig et al., 2001 ). 
 
ApG-primed transcription assay 
 The transcriptional activity of the viral polymerase can be tested using an ApG 
transcription assay where the 3’ and 5’ RNA and the dinucleotide primer ApG 
(Biosynthesis) are provided. ApG is extended using the 3’ RNA template by the 
polymerase. This gives an end result of a RNA fragment. The 5’ vRNA template (5’-
AGUAGAAACAAGGCC-3’) and the 14-nucleotide (nt) 3’ vRNA template (5’-
GGCCUGCUUUUGCU-3’) from the PA gene of the influenza virus were purchased 
from Dharmacon. Other 3’ templates used were 50-nt long and 137-nt long, and these 
encode the sequences from the 3’ end of the Nanchang PA gene. The 50-nt template was 
purchased from Integrated DNA Technologies, while the 137-nt RNA template was 
prepared by in vitro transcription (Aggarwal, et al., 2010).  
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The transcription reactions were performed as elsewhere (Aggarwal, et al., 2010; 
Fodor, et al., 2002). The reactions were 10µL reaction mixtures at 37°C containing 
transcription buffer (25mM Tris-Cl, pH 7.5, 100mM KCl, 5mM Mg(OAC)2, 0.1mM 
EDTA, 2mM DTT, 0.25µL Nonidet P-40, 12.5% glycerol), IAV polymerase complex, 
0.25 U/µl RNasin, 0.3mM ApG, 1.6µM 14-nt 3’vRNA, 1.6µM 5’ vRNA, 0.08µM 
radioactive α-32P-GTP /UTP/ATP (3000 Ci/mmole, Perkin Elmer), and 500mM non-
radioactive ATP, UTP, GTP and CTP. The reaction was stopped after 1 hour with the 
addition of 5µl trichloroacetic acid (TCA) dye, and was then denatured for 3 min at 95°C. 
Transcription products were separated by 8M urea denaturing 18-20% polyacrylamide 
gel electrophoresis. The dried gels were analyzed with autoradiography using a 
PhosphorImager (Molecular Dynamics) and the intensity of the products was quantified 
using OptiQuant (Version 3.10, Packard Instrument).  
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RESULTS 
 
 
 The first part of this project involved optimizing the purification process of the 
PA239-716-GST and PA657-716-GST constructs.  This was necessary because when 
following the procedure as described by Amersham in the GST fusion kit, we got 
insoluble expression and low protein yields. First, we used molecular imaging software 
Visual Molecular Dynamics (VMD) to input the protein sequence and visualize the 
interactions between the PA constructs and PB1 binding regions (Figure-2). This 
software reads Protein Data Bank files and then displays the structure in a variety of 
ways. It allowed us to visualize the structure of the proteins and see how they fit together. 
 
 
Figure 2: Visual Representations of the PA/PB1 Interactions. Shown here is a visualization of how the 
PA and PB1 molecules fit together using the VMD software. On the left is the sphere representation with 
the PA657-716 peptide in red and the binding region of PB1(1-25) in blue. On the right is the ribbon and tube 
representation of the whole PA molecule (blue) and the PB1 peptide (yellow). 
 
 
Using this software, we were able to determine an ideal location for a mutation 
which would prevent binding between the PA and PB1 peptides, and could serve as our 
negative control for the Fluorescence Polarization Assay. For the PA239-716, the mutation 
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was L640D.  For the PA657-716 protein, the mutation was L666D.  The addition of the 
aspartic acid in exchange for the leucine changed the structure of the protein just enough 
to prevent binding to the PB1 peptide. 
With the constructs and mutants created, we were able to begin purifying the 
proteins needed for our assay system. Once the proteins were induced overnight, the cells 
were lysed open with lysis buffer [20mM Tris-Cl pH 8, 500mM NaCl, 500mM urea]. The 
lysis buffer was refined for optimal lysing of the cells. 1% Triton X, a detergent, and 1x 
Protease Inhibitor (Roche) were then added. Finally, rLyzozyme (Novagen) was added. 
We used 150µL for the larger protein (PA239-716-GST), and only 2µL for the smaller 
protein (PA657-716-GST). The larger PA239-716-GST cell suspension was then sonicated 4 
times for 30 seconds each time. For the smaller protein, the sonication disrupted the 
proteins, so a 3 freeze-thaw cycles were performed in an ethanol-dry ice bath for that 
suspension. The suspension was then spun down, and applied to a column with 
Glutathione Sepharose beads (which bind to the GST protein) and incubated 2 hours at 
4°C. The incubation time was optimized to allow for enough binding time for the GST, 
but to prevent non-specific binding. Finally, the column was washed with 1x GST 
wash/bind buffer (Amersham), and eluted 5x with 1x Reduced Glutathione (Amersham). 
The wash and elution steps were adjusted for purity of the final product. The resulting 
proteins, as well as samples taken at each step, were run on a gel to observe the 
purification (Figure 3). 
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Figure 3: Purification of PA Constructs Using GST Fusion System. The gels shown are of the 
optimized conditions for each protein, run on a 10% SDS-PAGE gel which was Coomassie stained. In A is 
the PA657-716 protein, while in B is the PA239-716 protein.  In addition, the mutant proteins for each construct 
were each purified in the same way (gels not shown). 
 
With the GST fusion purification process optimized, the process could be scaled 
up in order to put the proteins to use in the new assay system. Up to 6L of initial culture 
could be purified at one time yielding high quality protein at around 2mg/mL. 
The second part of the project involved optimizing a transcription assay system 
for use in a mammalian cell system. Another lab member had previously published 
findings showing the Nanchang influenza polymerase complex was a high fidelity 
protein. The polymerase in this study was purified from insect cells, and only one strain 
was tested. This project meant to test polymerase complexes which were purified from a 
mammalian lung cell line, as well as compare the fidelity and activity of the polymerase 
between different strains. 
A 
B 
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Using the previously described system, there was no activity from any of the 
purified polymerase complexes. This can be seen in Figure 4. The negative control 
(previously tested Nanchang polymerase) showed high activity (seen in lanes one through 
three). However, none of the other polymerase complexes showed any activity at all. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Initial Transcription Assay. The 3 bands on the left are the purified Nanchang virus used 
previously in this assay system, serving as a control. In the rest of the rows, no activity can be seen from 
any of the purified complexes. Along the top designates which strain was used, and within each strain three 
different concentrations of polymerase were tried. 
 
 
After the initial attempt did not work, a different assay system was tried. It had all 
the same components as described above, except 1mM ATP/CTP/UTP, 2µM GTP, and 
0.08µM radioactive α-32P-GTP. In this system, unlike the other one, there was a NTP 
bias, with 1000 fold less GTP in the reaction than the rest of the nucleotides. However, 
Nan WSN Cal09 1918 H5N1 
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this new system with the bias gave much better results when used with the polymerase 
complex from the 1918 strain (which was selected for its high activity). This assay with 
the nucleotide bias was then tried with the different templates (14-nt, 30-nt, 50-nt, and 
137-nt) to see if the template made a difference. The results of this test can be seen below 
in Figure 5. With this test of different templates, the 137-nt template would work the best 
for future use in a misincorporation assay. There were no secondary bands which would 
hinder the visualization of the stop sites in the misincorporation assay. This template also 
was long enough to utilize in the misincorporation assay. 
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Figure 5: Transcription Assay with Different Templates. The left five lanes are the 1918 polymerase, 
while the right five used the California 09 Swine polymerase. Each polymerase had a reaction with the 14-
nt template, the 30-nt template, the 50-nt template, the 137-nt template, and finally a loop template.  
 
 
However, even though the 137-nt template worked, there was nowhere near the 
activity that can be seen with the 14-nt template. Additionally, the NTP pool was still 
biased, which is believed to lead to an inaccurate measure of true activity of the 
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polymerase, because the GTP pool is a limiting factor compared to the other nucleotides. 
It is unclear why the unbiased NTP system worked for the polymerase proteins purified 
from the insect cells and not from the human cells. When a further study of the effect of 
concentration of NTPs was performed, it was found that the ratio of the cold GTP to the 
radioactive labeled GTP had to be similar for there to be activity (Figure 6). 
Additionally, as long as there were similar amounts of hot and cold GTP, the amount of 
the other three NTPs did not matter as much (until it was in the 10,000 times higher 
range). 
 
Component 1. 2. 3. 4. 5. 6. 7. 8. 
ATP/UTP/CTP 20μM 100 μM 500 μM 1000μM 20 μM 100 μM 500 μM 1000μM 
GTP .1 μM .1 μM .1 μM .1 μM 20 μM 100 μM 500 μM 1000μM 
*GTP .08 μM .08 μM .08 μM .08 μM .08 μM .08 μM .08 μM .08 μM 
Activity 
(1-5 scale) 
3 4 5 1 0 0 0 0 
 
Figure 6: Result of NTP Concentration Test. Each column is a separate reaction, as described above. The 
activity was ranked on a 0-5 scale with 0 being no activity and 5 being large amounts of activity. The 
effects varying concentrations of the ATP/CTP/UTP was tested, as well as matching the cold GTP 
concentration to the other NTP concentrations. 
 
From the tests performed above, we can conclude that the assay conditions 
described in Aggarwal, et al., 2010, do not work for the purified proteins from the 
mammalian cell line. We speculate that in the insect system, some other host proteins are 
playing a role in NTP sequestering or aiding the polymerase in some unknown way. 
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DISCUSSION 
 
This project optimized the preparation of the PA-GST fusion proteins to 
eventually be used in the Fluorescence Polarization assay along with the PB1 peptide 
which was pre-labeled with a Rhodamine chromophore. Optimizing the purification 
process took much trial and error. Each purification step took multiple days to complete, 
so it was a slow process. 
However, in the end, a system was created for each of the new proteins which 
worked well and could be scaled up to create the large quantities of PA which were 
needed for the Fluorescence Polarization assay. The resulting protein was of high quality 
with few imperfections and a relatively concentrated protein. The production of the PA 
protein has been the limiting factor in the FP assay, so if there were ways to further 
improve the process that would be helpful. 
To date, numerous chemical compounds have been screened from a chemical 
library at the University of Rochester High Throughput Screening (HTS) Core Facility. 
The fluorescence polarization assay has already been optimized for binding and there 
have even been a few hits on chemical compounds which have been found to disrupt the 
binding between the PB1 peptide and the PA constructs. One of these compounds is 
ribavirin, an antiviral drug used to treat RSV. This compound is undergoing further in 
vitro tests to investigate the extent of the binding disruption. If chemical compounds are 
found, they could eventually turn into new antiviral drugs, for which there is a strong 
need (McKimm-Breschkin et al., 2007). These drugs would have limited resistance 
because the polymerase is a highly conserved structure (Obayashi, 2008). 
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The second portion of the project began to improve upon a transcription assay 
system that was created to test the fidelity of influenza polymerase. However, the original 
assay was developed for a polymerase complex that was purified out of insect cells 
(Aggarwal et al., 2010), and it did not work with our mammalian system. It is important 
to use the mammalian system because a more accurate picture is seen of what the 
transcription rates are actually like during a human infection. 
This portion of the project was difficult because there really was not much 
headway made in improving the assay system. The polymerase complex proteins were 
purified from A549 cells successfully and are ready to be used in assays.  Some 
polymerase activity was gained using the two different assay systems that were tried in 
this project. 
In the future, there needs to be further testing to determine what the ideal NTP 
concentration is for the transcription assays. Once that is determined, the activity of all 
the polymerase complexes from different strains can be compared and quantitated in the 
assay. This will give insight into whether the polymerase complex has anything to do 
with the virulence of the influenza virus. Additionally, mis-incorporation assays can be 
performed with the polymerase complexes to determine their level of fidelity, or 
accuracy. This will also give researchers new information about the influenza virus which 
someday could be helpful in preventing pandemics or developing vaccines.  
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